On November 7 2023, DENALI THERAPEUTICS ($NASDAQ:DNLI) revealed their financial results for the three-month period ending September 30 2023. Total revenue was USD 1.3 million, a decline of 64.3% compared to the same quarter of the previous year. Net income was USD -99.4 million in the third quarter of FY2023, a reduction from the net loss of -103.3 million recorded for the corresponding period of FY2022.
DENALI THERAPEUTICS reported their earnings results for the third quarter of Fiscal Year 2023 on Tuesday. The company’s stock opened at $20.8 and closed at $21.2, indicating a 2.3% growth in the stock’s value from their prior closing price of $20.8. This is an impressive performance in the stock market, given the current economic climate. It reflects a continued confidence in the company’s strategy and products. The company has been steadily growing over the past several quarters, and these results indicate that their efforts are paying off. DENALI THERAPEUTICS has made significant investments in research and development, and they are reaping the rewards of those investments now.
Additionally, their broad portfolio of products and services is allowing them to capitalize on a wide range of opportunities in the market. Overall, DENALI THERAPEUTICS has demonstrated that they have what it takes to be a successful player in the biopharmaceuticals market. With their strong results in this latest quarter, investors and analysts alike can be confident that their strategy and products are on track for continued growth and success in the future. Live Quote…
About the Company
Ownership (Institutional/ Fund Holdings)
Below shows the total revenue, net income and net margin for Denali Therapeutics. More…
Income Statement Reports (Yearly/ Quarterly/ LTM)
Cash Flow Snapshot
Below shows the cash from operations, investing and financing for Denali Therapeutics. More…
Cash Flow Statement (Yearly/ Quarterly/ LTM)
Cash Flow Supplement
Balance Sheet Snapshot
Below shows the total assets, liabilities and book value per share for Denali Therapeutics. More…
Balance Sheet (Yearly/ Quarterly)
Balance Sheet Supplement
||Book Value Per Share
Key Ratios Snapshot
Some of the financial key ratios for Denali Therapeutics are shown below. More…
Income Statement Ratios
Balance Sheet Ratios
Cash Flow Ratios
Other Supplementary Items
|3Y Rev Growth
||3Y Operating Profit Growth
Analysis – Denali Therapeutics Stock Fair Value Calculator
At GoodWhale, we recently conducted an analysis of DENALI THERAPEUTICS‘s wellbeing. Our proprietary Valuation Line showed that the fair value of DENALI THERAPEUTICS’ stock is around $75.6. However, currently DENALI THERAPEUTICS’ stock is trading at $21.2, meaning that it is undervalued by 72.0%. More…
Star Chart Analysis
The biotech sector is full of companies vying for market share andDenali Therapeutics Inc is no different. It competes againstG1 Therapeutics Inc, Kezar Life Sciences Inc, and Ryvu Therapeutics SA, among others.
G1 Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of small molecule therapeutics for the treatment of cancer. The company’s lead product candidate is trilaciclib, which is in Phase III clinical trials for the treatment of small cell lung cancer. G1 Therapeutics Inc has a market cap of 486.46M as of 2022 and a Return on Equity of -117.43%.
– Kezar Life Sciences Inc ($NASDAQ:KZR)
Kezar Life Sciences Inc is a clinical-stage biotechnology company that focuses on the discovery, development, and commercialization of novel small molecule therapeutics to treat autoimmune and other inflammatory diseases. The company has a market cap of 506.62M as of 2022 and a Return on Equity of -14.21%. Kezar Life Sciences Inc is headquartered in South San Francisco, California.
– Ryvu Therapeutics SA ($LTS:0RKT)
Ryu Therapeutics is a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of serious and life-threatening diseases. The company’s lead product candidate, RT-001, is a first-in-class, investigational gene therapy for the treatment of patients with wet age-related macular degeneration. The company is also developing RT-002, a gene therapy for the treatment of patients with X-linked retinitis pigmentosa, and RT-003, a gene therapy for the treatment of patients with Usher syndrome type 1c.
DENALI THERAPEUTICS reported their third quarter FY2023 earnings results on November 7 2023, revealing total revenue of USD 1.3 million, a decrease of 64.3% from the same period the previous year. Net income for the quarter was reported to be USD -99.4 million, an improvement from the prior year’s net loss of -103.3 million. Investors looking to invest in DENALI THERAPEUTICS should consider the company’s decreasing revenue and increasing net losses, as well as its potential for future growth and long-term profitability. Market analysts advise investors to conduct thorough research and analysis before investing in this company.